Indiana Lawyers Challenge Weisheit Execution Over Drug Supplier

Indiana is preparing to execute Jeffrey Weisheit at the Indiana State Prison in Michigan City, with the procedure scheduled for midnight Central Time on November 5, 2026. However, his attorneys are seeking intervention from Gov. Mike Braun, alleging that concerns surrounding the state's lethal injection drug supplier raise serious questions about execution safety.

Weisheit, 50, was sentenced to death for the 2010 murders of siblings Alyssa Lynch, 8, and Caleb Lynch in an arson attack at their Evansville home. His lawyers have requested that Braun commute his sentence to life imprisonment without parole and investigate the state's procurement procedures.

The legal challenge centers on Pharmaneek, an Indianapolis-based pharmacy allegedly connected to Indiana's supply of pentobarbital. The pharmacy faces regulatory action following inspections that identified problems involving drug storage, expired medications and inadequate temperature monitoring.

An inventory record obtained by NBC News shows that the Indiana Department of Correction added six vials of pentobarbital to its prison supply on October 29. An invoice submitted with Weisheit's clemency application lists a payment of $275,000, substantially exceeding the typical commercial price of $15,120 to $16,250 for injectable pentobarbital.

The invoice was heavily redacted and did not identify the transaction date or supplier. However, documents relating to a September 2025 purchase for the same amount contained an address beneath a redaction that corresponded to Pharmaneek's location.

Weisheit's attorney Joe Perkovich criticized the state's handling of execution-related drug procurement.

"Laid bare, the apparent conduct here is patently unworthy of the public’s confidence in the solemn exercise of state power in taking a human being’s life in the name of the people," Perkovich said in a statement.

The defense also cited Tennessee's September 30 execution attempt involving Christa Pike, arguing that Indiana's procedures could face comparable complications.

In their clemency application, Weisheit's attorneys described Indiana's protocol as "more susceptible to catastrophic failures such as the one that placed Ms. Pike in a coma," and raised concerns about the pharmacy's record of "rampant mishandling of drugs."

Regulatory inspections identified several alleged violations at Pharmaneek. Inspectors discovered expired medications during a "random inspection of active pharmacy shelves," while other findings involved improperly labeled containers and inconsistent temperature records.

A March 2026 inspection report from the Food and Drug Administration described the facility's condition in particularly serious terms.

The FDA report stated that the "facility is not maintained in a good state of repair, creating unsanitary conditions whereby drug products may be contaminated with filth." The agency also clarified that its findings did not constitute a final determination of regulatory compliance.

Indiana licensing records show that Pharmaneek's pharmacy license and controlled substance registration were on probation. A legal filing dated September 24 indicated that the Indiana Board of Pharmacy had ordered the company to appear and "show cause" why its license "should not be suspended on an emergency basis or subjected to the imposition of further sanctions."

The hearing was subsequently rescheduled to November 9, four days after Weisheit's planned execution. According to the defense application, Pharmaneek is prohibited from compounding custom medications, although the attorneys allege that it may have acted as an intermediary supplying commercially manufactured pentobarbital.

Previous court filings concerning Roy Lee Ward's October 2025 execution stated that Indiana's pentobarbital was manufactured by a pharmaceutical company rather than a compounding pharmacy and distributed "without any post-manufacturing customizations."

Drug manufacturers have raised objections to their products being used in executions. Hikma, one of the US manufacturers of pentobarbital, said it had no purchase agreement with Pharmaneek.

Hikma representative Steven Weiss said the company maintained restrictions on the use of its pharmaceutical products in capital punishment.

"We have strict prohibitions and controls intended to prevent the use of our medicines in capital punishment," Weiss said.

Indiana Attorney General Todd Rokita's spokesperson defended the state's execution preparations and questioned the defense's disclosure of the pharmacy's alleged involvement.

The spokesperson said the office was "confident in the ability to safely and lawfully carry out the scheduled execution."

The spokesperson also criticized the attorneys for publicly identifying a pharmacy allegedly connected to the state's execution drug supply, saying they "have publicly identified a pharmacy that they claim is connected to Indiana’s execution-drug supply, despite state law requiring supplier information to remain confidential."

Meanwhile, Vanderburgh County Prosecutor Diana Moers opposed Weisheit's clemency request in a statement released October 17. She described the lasting impact of the children's murders on their family and the local community.

Moers said the county "was, and still is, consumed by news of the horrible murders of two completely innocent children and left with imagining the pain and grief felt by their mother."

She maintained that Weisheit had exhausted his available constitutional protections and stated that "exhausted his constitutional protections and so the answer is final—the death penalty should be imposed."

Indiana's Department of Correction scheduled Weisheit's execution for midnight Central Time at Indiana State Prison in Michigan City, while the pharmacy's regulatory hearing remained scheduled for November 9.